Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Sutro Biopharma Reports $9.1 Million Third-Quarter Revenue

None

Sutro Biopharma (STRO) reported third-quarter 2026 revenue of $9.1 million and a net loss of $31.5 million, compared with revenue of $9.7 million and a net loss of $56.9 million a year earlier. Net loss per share was $1.90, versus $6.66 in the prior-year quarter.

The company ended September with $142.2 million in cash, cash equivalents and marketable securities and said its current operating plan is expected to support operations into the first half of 2028.

  • R&D and G&A expenses totaled $31.0 million, compared with $48.6 million in the third quarter of 2025.
  • STRO-004 dose optimization is continuing, with a clinical update and expansion cohorts planned for the first half of 2027.
  • STRO-006 entered the clinic after the first patient was dosed in October; an initial update is expected in the second half of 2027.
  • Astellas began dosing patients in a second dual-payload iADC program targeting B7-H3, triggering a $10 million milestone payment received in October.

$STRO Hedge Fund Activity

We have seen 63 institutional investors add shares of $STRO stock to their portfolio, and 37 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles